Format

Send to

Choose Destination
JAMA Pediatr. 2019 Nov 25. doi: 10.1001/jamapediatrics.2019.4509. [Epub ahead of print]

Omalizumab for Atopic Dermatitis: Overtreatment or Lifesaver?

Author information

1
Center for Healthcare Research in Pediatrics, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, Massachusetts.

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center